Cargando…
A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations
A key step in the development of medicinal products is the research and validation of selective and sensitive analytical methods for the control of impurities from synthesis and degradation. As most impurities are similar in structure to the drug substance, the achievement of chemo-selective conditi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824232/ https://www.ncbi.nlm.nih.gov/pubmed/36615620 http://dx.doi.org/10.3390/molecules28010431 |
_version_ | 1784866359180525568 |
---|---|
author | Mammone, Francesca Romana Zanitti, Leo Puxeddu, Michela La Regina, Giuseppe Silvestri, Romano Borioni, Anna Cirilli, Roberto |
author_facet | Mammone, Francesca Romana Zanitti, Leo Puxeddu, Michela La Regina, Giuseppe Silvestri, Romano Borioni, Anna Cirilli, Roberto |
author_sort | Mammone, Francesca Romana |
collection | PubMed |
description | A key step in the development of medicinal products is the research and validation of selective and sensitive analytical methods for the control of impurities from synthesis and degradation. As most impurities are similar in structure to the drug substance, the achievement of chemo-selective conditions is usually challenging. Herein, a direct and highly selective ultra-high-performance liquid chromatographic method for determining the assay and related substances content in medicinal products containing rosuvastatin calcium salt (RSV) is presented. RSV is used to treat high cholesterol levels and prevent heart attacks and strokes. The most engaging feature of this method was the baseline separation of all organic related substances listed in the European Pharmacopoeia (EP) monograph for the RSV tablets, achieved for the first time in less than 15 min using the Acquity BEH C18 (100 mm × 2.1 mm, 1.7 μm) column under reversed-phase isocratic conditions. The mobile phase adopted for the chemo-selective analysis does not contain buffers but instead contains trifluoroacetic as an acid additive. The chromatographic method was validated according to the guidelines of the International Conference on Harmonization (ICH) and proved to be linear, precise and accurate for determining the content of RSV and related chiral substances in tablet formulations. |
format | Online Article Text |
id | pubmed-9824232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98242322023-01-08 A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations Mammone, Francesca Romana Zanitti, Leo Puxeddu, Michela La Regina, Giuseppe Silvestri, Romano Borioni, Anna Cirilli, Roberto Molecules Article A key step in the development of medicinal products is the research and validation of selective and sensitive analytical methods for the control of impurities from synthesis and degradation. As most impurities are similar in structure to the drug substance, the achievement of chemo-selective conditions is usually challenging. Herein, a direct and highly selective ultra-high-performance liquid chromatographic method for determining the assay and related substances content in medicinal products containing rosuvastatin calcium salt (RSV) is presented. RSV is used to treat high cholesterol levels and prevent heart attacks and strokes. The most engaging feature of this method was the baseline separation of all organic related substances listed in the European Pharmacopoeia (EP) monograph for the RSV tablets, achieved for the first time in less than 15 min using the Acquity BEH C18 (100 mm × 2.1 mm, 1.7 μm) column under reversed-phase isocratic conditions. The mobile phase adopted for the chemo-selective analysis does not contain buffers but instead contains trifluoroacetic as an acid additive. The chromatographic method was validated according to the guidelines of the International Conference on Harmonization (ICH) and proved to be linear, precise and accurate for determining the content of RSV and related chiral substances in tablet formulations. MDPI 2023-01-03 /pmc/articles/PMC9824232/ /pubmed/36615620 http://dx.doi.org/10.3390/molecules28010431 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mammone, Francesca Romana Zanitti, Leo Puxeddu, Michela La Regina, Giuseppe Silvestri, Romano Borioni, Anna Cirilli, Roberto A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations |
title | A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations |
title_full | A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations |
title_fullStr | A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations |
title_full_unstemmed | A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations |
title_short | A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations |
title_sort | novel validated uhplc method for the estimation of rosuvastatin and its complete impurity profile in tablet formulations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824232/ https://www.ncbi.nlm.nih.gov/pubmed/36615620 http://dx.doi.org/10.3390/molecules28010431 |
work_keys_str_mv | AT mammonefrancescaromana anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT zanittileo anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT puxeddumichela anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT lareginagiuseppe anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT silvestriromano anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT borionianna anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT cirilliroberto anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT mammonefrancescaromana novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT zanittileo novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT puxeddumichela novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT lareginagiuseppe novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT silvestriromano novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT borionianna novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations AT cirilliroberto novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations |